Company intelligence / Profile preview

ColoFlux

Ownership: Private
Development stage: Preclinical

Overview

ColoFlux has developed an optical sensing system called CALM that uses proprietary AI-driven algorithms to detect anastomotic leakage as early as 24 hours after colorectal surgery. The system integrates multiple patient health markers for prompt detection and improved outcomes. No published clinical trial results are referenced on their website.

Therapeutic areas: Gastroenterology
Modalities: DeviceAlgorithm-based diagnostics (AI-powered)
Industry: Physiological Monitoring

Partnerships

None publicly listed or referenced online as of June 2025.

Beyond the preview

Go deeper on ColoFlux.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ColoFlux.

Explore the full profile